Impact of Oligonol to Cardiometabolic Risk and Muscular Health
NCT ID: NCT03788577
Last Updated: 2023-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2018-12-04
2020-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Krill Oil and Muscle in Older Adults
NCT04048096
Effect of Ishige Okamurae Extract on Musculoskeletal Biomarkers in Adults With Relative Sarcopenia
NCT04617951
Carnitine Supplementation and Skeletal Muscle Mass
NCT05009641
Muscle Health and Recovery in Older Adults
NCT06205537
Krill Oil and Resistance Exercise in Older Adults
NCT05869513
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oligonol intake group
This experimental arm will be applied for Oligonol 200mg/tab 1 tab per day. The program will last for 12 weeks.
Oligonol intake
Major intervention of Oligonol component , as suggested Oligonol safe dose for adults is 200mg per day.
Placebo group
This Placebo arm will be given capsules made of starch 1 tab per day. The program will last for 12 weeks.
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oligonol intake
Major intervention of Oligonol component , as suggested Oligonol safe dose for adults is 200mg per day.
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with following characteristics:
* feeling loss in activity.
* detecting decline in self's walking speed.
* feeling tired of doing everything.
* having fallen down last year.
* People can accept undergoing MRI
* People willing to follow the program and cooperate with us for following tracking.
* People who are neither vegan nor vegetarian
Exclusion Criteria
* People with any disease affecting their limbs, including:
* having fracture on limbs in the past 6 months.
* having severe arthritis in the past 6 months
* any other whom PI recognized as weak control of their nervous system( e.g.: Parkinson's disease and stroke).
* People with intermittent limp caused by peripheral artery diseases
* People with weak control of mental disorder
* People with weak control of Cardiopulmonary disease
* People with weak control of Malignant tumor
* People with weak control of kidney diseases (GFR \< 30 mL/min/1.73 m2 for at least 3 months)
* People with visual impairment and hearing disorder who cannot complete the program.
* People who are unable to undertake MRI
* Any other condition that PI recognized as not suitable.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Yang Ming Chiao Tung University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Liang-Kung Chen, MD.PhD.
Role: PRINCIPAL_INVESTIGATOR
Center for Healthy Longevity and Aging Sciences, National Yang Ming University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taipei Veteran General Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-05-004B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.